Personalized Medicine (PM) Market by Product - Global Industry Analysis and Forecast to 2022

Published On : November 2017 Pages : 116 Category: Biotechnology Report Code : HC11358

Industry Trend Analysis

In 2012, the global personalized medicine market was evaluated around USD 806.97 billion and is expected to reach approximately USD 5208.68 billion by 2022 while registering itself at a compound annual growth rate (CAGR) of 12.01% over the forecast period. Major driving factors of the global market are increasing development of whole genome, companion diagnostics, next-generation sequencing technology, and rising retail clinics. Rising healthcare spending levels stimulating the demand for an efficient cancer diagnostic procedure, rising incidence of cancer and growing utilization of amalgamation biomarkers for diagnostics are some factors projected to boost the growth of the global market. Rising implementation of next-generation sequencing by medical practitioners and clinicians for genetic mapping of patients worldwide and increasing support for the personalized drug by regulatory and reimbursement landscape are also expected driving factors for global demand over 2022. Global market growth is also projected to augment via the new drugs introduction that is linked and companion diagnostics, and increasing usage of accurate and extremely sensitive genetic diagnostic method for disease testing as well as risk assessment. The expected rise in advanced DNA diagnostic use along with the decline in implementation price for whole genome sequencing is anticipated to significantly increased rates.

Product Outlook and Trend Analysis

The personalized medicine industry comprehends custom-made medical products split into PM therapeutics, PM diagnostics, nutrition & wellness, and PM care. PM diagnostics and therapeutics cover direct-to-consumer diagnostics, genetic testing, esoteric lab tests and services, medical devices and pharmaceutical & genomic medicine. PM therapeutics and diagnostics sections are anticipated to grow at a significant rate over the next few years due to the increasing adoption of DNA/RNA screening for medical treatment and therapy and expansion of next-generation sequencing over the forecast years. Introduction and development of companion diagnostics and linked medicines are also projected to lead towards the global personalized medicine market growth. Nutritional wellness and medical care segments involve health information technology, telemedicine, retail nutrition, diseases management, alternative and complementary medicine. These reported for a considerably large section of the global market revenue in 2014 and are anticipated to maintain the leading market position till 2022, due to excessive usage rates, across the distribution and counter sale, growth, and development of retail clinics and growing complementary medicine adoption. Further integration and implementation of healthcare IT systems and telemedicine with hospital workflow frameworks and operation are also anticipated to boost the demand for the global personalized medicine market during the next few years. Although this industry has key application in oncology currently, it is anticipated that during the forecast years, the market will experience growth in applications section like CNS disorders, psychiatry, and cardiovascular & infectious diseases.

Regional Outlook and Trend Analysis

In 2014, North American regional personalized medicine market ruled global demand, due to supportive NIH policies and government funding, rising adoption of clinical practitioners, central consolidation of healthcare IT and EHR systems with hospital operations, and incorporation into clinical trials. Technological advancements of next-generation sequencing ensuing in cost decline of genomic sequencing is too an elevated impact providing factor projected to bestow towards the growth of the market. Though, the Asia-Pacific regional personalized medicine industry is anticipated witness major gains during the forecasted years due to the existence of a considerably large base of unfulfilled industry demand, rising technological progression of the regional medical framework and rising awareness regarding genetic diagnostics, therapeutics, and genomic sequencing.

Competitive Outlook and Trend Analysis

Market players ruling personalized medicine market are occupied in the progression of these testing methodologies to improve public application rates of genetic therapeutic, personalized tailor-made therapy prescriptions and companion diagnostic tests. Major market players are Quest Diagnostics, 3G Biotech, Laboratory Corporation of America, Agendia NV, Abbott, AsuragenInc, CardioDx Inc., Becton Dickinson & Co., Foundation Medicine Inc., Siemens Healthcare Diagnostics Inc., Qiagen Inc., Amgen Inc., GE Healthcare, Bristol-Myers Squibb, Pfizer Inc., 23andMe, Sanofi, Illumina Inc., Astra Zeneca PLC, Roche Holding AG, Vertex Pharmaceuticals Inc., American Association for Cancer Research and Merck & Co. Inc.

The global personalized medicinemarket is segmented as follows –

By Product

  • PM Diagnostics
    • Genetic Testing
    • Direct-to-consumer Diagnostics
    • Esoteric Lab Services
    • Esoteric Lab Tests
  • PM Therapeutics
    • Pharmaceutical
    • Genomic Medicine
    • Medical Devices
  • Personalized Medical Care
    • Telemedicine
    • Healthcare Information Technology
    • Diseases Management
  • Personalized Nutrition & Wellness
    • Retail Nutrition
    • Complementary Medicine
    • Alternative Medicine

By Region

  • North America
  • U.S
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia Pacific
  • Rest of the World
  • Brazil
  • South Africa
  • Saudi Arabia
  • United Arab Emirates
  • Others

Some of the key questions answered by the report are:

· What was the market size in 2012 and forecast from 2013 to 2022?

· What will be the industry market growth from 2013 to 2022?

· What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?

· What are the major segments leading the market growth and why?

· Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

  • Personalized Medicine (PM) Market, By Product, Estimates and Forecast, 2012-2022 ($Million)
    • PM Diagnostics
      • Genetic Testing
      • Direct-to-consumer Diagnostics
      • Esoteric Lab Services
      • Esoteric Lab Tests
    • PM Therapeutics
      • Pharmaceutical
      • Genomic Medicine
      • Medical Devices
    • Personalized Medical Care
      • Telemedicine
      • Healthcare Information Technology
      • Diseases Management
    • Personalized Nutrition & Wellness
      • Retail Nutrition
      • Complementary Medicine
      • Alternative Medicine
  • Personalized Medicine (PM) Market, By Region, Estimates and Forecast, 2012-2022 ($Million)
    • North America
  • North America Personalized Medicine (PM) Market, By Country
  • North America Personalized Medicine (PM) Market, By Product
    • U.S. Personalized Medicine (PM) Market, By Product
    • Canada Personalized Medicine (PM) Market, By Product
    • Mexico Personalized Medicine (PM) Market, By Product
    • Europe
  • Europe Personalized Medicine (PM) Market, By Country
  • Europe Personalized Medicine (PM) Market, By Product
    • Germany Personalized Medicine (PM) Market, By Product
    • France Personalized Medicine (PM) Market, By Product
    • UK Personalized Medicine (PM) Market, By Product
    • Italy Personalized Medicine (PM) Market, By Product
    • Spain Personalized Medicine (PM) Market, By Product
    • Rest of Europe Personalized Medicine (PM) Market, By Product
    • Asia-Pacific
      • Asia-Pacific Personalized Medicine (PM) Market, By Country
      • Asia-Pacific Personalized Medicine (PM) Market, By Product
        • Japan Personalized Medicine (PM) Market, By Product
        • ChinaPersonalized Medicine (PM) Market, By Product
        • Australia Personalized Medicine (PM) Market, By Product
        • India Personalized Medicine (PM) Market, By Product
        • South Korea Personalized Medicine (PM) Market, By Product
        • Rest of Asia-Pacific Personalized Medicine (PM) Market, By Product
    • Rest of the World
      • Rest of the World Personalized Medicine (PM) Market, By Country
      • Rest of the World Personalized Medicine (PM) Market, By Product
        • Brazil Personalized Medicine (PM) Market, By Product
        • South Africa Personalized Medicine (PM) Market, By Product
        • Saudi Arabia Personalized Medicine (PM) Market, By Product
        • Turkey Personalized Medicine (PM) Market, By Product
        • United Arab Emirates Personalized Medicine (PM) Market, By Product
        • Others Personalized Medicine (PM) Market, By Product

Table of Contents

1.       Introduction

1.1.       Report Description

1.2.       Research Methodology

1.2.1.  Secondary Research

1.2.2.  Primary Research

2.       Executive Summary

2.1.       Key Highlights

3.       Market Overview

3.1.       Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.       Market Dynamics

3.2.1.  Drivers

3.2.1.1.    Increasing number of associated diagnostics

3.2.1.2.    Rising healthcare spending generating development of effective PM diagnostic & therapeutic

3.2.1.3.    Growing prevalence of cancer

3.2.2.  Restraints

3.2.2.1.    Lack of Technologies

3.2.2.2.    Absence of appropriate intellectual property regulations for personalized medical technologies

3.2.3.  Opportunities

3.2.3.1.    Technological Advancement in Development of Personalized Medicines

4.       Personalized Medicine (PM) Market, By Product

4.1.       Introduction

4.2.       Personalized Medicine (PM) Market Assessment and Forecast, By Product, 2012-2022

4.3.       PM Diagnostics

4.3.1.  Market Assessment and Forecast, By Type, 2012-2022 ($Million)

4.3.2.  Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.3.3.  Genetic Testing

4.3.3.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.3.4.  Direct-to-consumer Diagnostics

4.3.4.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.3.5.  Esoteric Lab Services

4.3.5.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.3.6.  Esoteric Lab Tests

4.3.6.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.4.       PM Therapeutics

4.4.1.  Market Assessment and Forecast, By Type, 2012-2022 ($Million)

4.4.2.  Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.4.3.  Pharmaceutical

4.4.3.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.4.4.  Genomic Medicine

4.4.4.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.4.5.  Medical Devices

4.4.5.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.       Personalized Medical Care

4.5.1.1.    Market Assessment and Forecast, By Type, 2012-2022 ($Million)

4.5.1.2.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.3.    Telemedicine

4.5.1.3.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.4.    Healthcare Information Technology

4.5.1.4.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.5.    Diseases Management

4.5.1.5.1.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.6.    Personalized Nutrition & Wellness

4.5.1.6.1.    Market Assessment and Forecast, By Type, 2012-2022 ($Million)

4.5.1.6.2.    Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.6.3.    Retail Nutrition

4.5.1.6.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.6.4.    Complementary Medicine

4.5.1.6.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)

4.5.1.6.5.    Alternative Medicine

4.5.1.6.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)

5.       Personalized Medicine (PM) Market, By Region

5.1.       Introduction

5.2.       Personalized Medicine (PM) Market Assessment and Forecast, By Region, 2012-2022 ($Million)

5.3.       North America

5.3.1.  Market Assessment and Forecast, By Country, 2012-2022 ($Million)

5.3.2.  Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.3.3.  U.S.

5.3.3.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.3.4.  Canada

5.3.4.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.3.5.  Mexico

5.3.5.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.4.       Europe

5.4.1.  Market Assessment and Forecast, By Country, 2012-2022 ($Million)

5.4.2.  Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.4.3.  Germany

5.4.3.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.4.4.  France

5.4.4.1.    Market Assessment and Forecast, By Products, 2012-2022 ($Million)

5.4.5.  UK

5.4.5.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.4.6.  Italy

5.4.6.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.4.7.  Spain

5.4.7.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.4.8.  Rest of Europe

5.4.8.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.       Asia-Pacific

5.5.1.  Market Assessment and Forecast, By Country, 2012-2022 ($Million)

5.5.2.  Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.3.  Japan

5.5.3.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.4.  China

5.5.4.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.5.  Australia

5.5.5.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.6.  India

5.5.6.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.7.  South Korea

5.5.7.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.5.8.  Rest of Asia-Pacific

5.5.8.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.       Rest of the World

5.6.1.  Market Assessment and Forecast, By Country, 2012-2022 ($Million)

5.6.2.  Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.3.  Brazil

5.6.3.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.4.  Turkey

5.6.4.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.5.  Saudi Arabia

5.6.5.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.6.  South Africa

5.6.6.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.7.  United Arab Emirates

5.6.7.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

5.6.8.  Others

5.6.8.1.    Market Assessment and Forecast, By Product, 2012-2022 ($Million)

6.       Company Profiles

6.1.       Abbott Laboratories

6.1.1.  Business Overview

6.1.2.  Product Portfolio

6.1.3.  Key Financials

6.1.4.  Strategic Developments

6.2.       GE Healthcare

6.2.1.  Business Overview

6.2.2.  Product Portfolio

6.2.3.  Key Financials

6.2.4.  Strategic Developments

6.3.       Cepheid

6.3.1.  Business Overview

6.3.2.  Product Portfolio

6.3.3.  Key Financials

6.3.4.  Strategic Developments

6.4.       Illumina Incorporated

6.4.1.  Business Overview

6.4.2.  Product Portfolio

6.4.3.  Key Financials

6.4.4.  Strategic Developments

6.5.       Dako A/S

6.5.1.  Business Overview

6.5.2.  Product Portfolio

6.5.3.  Key Financials

6.5.4.  Strategic Developments

6.6.       Biogen

6.6.1.  Business Overview

6.6.2.  Product Portfolio

6.6.3.  Key Financials

6.6.4.  Strategic Developments

6.7.       Exagen Diagnostics Inc.

6.7.1.  Business Overview

6.7.2.  Product Portfolio

6.7.3.  Key Financials

6.7.4.  Strategic Developments

6.8.       Decode Genetics Inc.

6.8.1.  Business Overview

6.8.2.  Product Portfolio

6.8.3.  Key Financials

6.8.4.  Strategic Developments

6.9.       Genelex Corporation

6.9.1.  Business Overview

6.9.2.  Product Portfolio

6.9.3.  Key Financials

6.9.4.  Strategic Developments

6.10.    Qiagen Incorporated

6.10.1.      Business Overview

6.10.2.      Product Portfolio

6.10.3.      Key Financials

6.10.4.      Strategic Developments

6.11.    Celera Diagnostics

6.11.1.      Business Overview

6.11.2.      Product Portfolio

6.11.3.      Key Financials

6.11.4.      Strategic Developments

6.12.    DNA Direct Inc

6.12.1.      Business Overview

6.12.2.      Product Portfolio

6.12.3.      Key Financials

6.12.4.      Strategic Developments

6.13.    Affymetrix Incorporated

6.13.1.      Business Overview

6.13.2.      Product Portfolio

6.13.3.      Key Financials

6.13.4.      Strategic Developments

6.14.    Agendia N.V.

6.14.1.      Business Overview

6.14.2.      Product Portfolio

6.14.3.      Key Financials

6.14.4.      Strategic Developments


List of Tables

List of Tables
Table 1.Personalized Medicine (PM) Market, By Product ($Million), 2012-2022
Table 2.PM Diagnostics Market, By Region ($Million), 2012-2022
Table 3.Genetic Testing Market, By Region ($Million), 2012-2022
Table 4.Esoteric Lab Services Market, By Region ($Million), 2012-2022
Table 5.Esoteric Lab Tests Market, By Region ($Million), 2012-2022
Table 6.PM Therapeutics Market, By Region ($Million), 2012-2022
Table 7.Pharmaceutical Market, By Region ($Million), 2012-2022
Table 8.Genomic Medicine Market, By Region ($Million), 2012-2022
Table 9.Medical Devices Market, By Region ($Million), 2012-2022
Table 10.Personalized Medical Care Market, By Region ($Million), 2012-2022
Table 11.Telemedicine Market, By Region ($Million), 2012-2022
Table 12.Healthcare Information Technology Market, By Region ($Million), 2012-2022
Table 13.Diseases Management Market, By Region ($Million), 2012-2022
Table 14.Personalized Nutrition & Wellness Market, By Region ($Million), 2012-2022
Table 15.Retail Nutrition Market, By Region ($Million), 2012-2022
Table 16.Complementary Medicine Market, By Region ($Million), 2012-2022
Table 17.Alternative Medicine Market, By Region ($Million), 2012-2022
Table 18.North America Personalized Medicine (PM) Market, By Country, 2012-2022 ($Million)
Table 19.North America Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 20.U.S. Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 21.Canada Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 22.Mexico Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 23.Europe Personalized Medicine (PM) Market, By Country, 2012-2022 ($Million)
Table 24.Europe Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 25.Germany Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 26.France Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 27.UK Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 28.Italy Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 29.Spain Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 30.Rest of Europe Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 31.Asia-Pacific Personalized Medicine (PM) Market, By Country, 2012-2022 ($Million)
Table 32.Asia-Pacific Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 33.Japan Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 34.China Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 35.Australia Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 36.India Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 37.South Korea Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 38.Rest of Asia-Pacific Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 39.Rest of the World Personalized Medicine (PM) Market, By Country, 2012-2022 ($Million)
Table 40.Rest of the World Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 41.Brazil Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 42.Turkey Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 43.Saudi Arabia Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 44.South Africa Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 45.United Arab Emirates Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 46.Others Personalized Medicine (PM) Market, By Product, 2012-2022 ($Million)
Table 47.Abbott Laboratories: Key Strategic Developments, 2015-2017
Table 48.GE Healthcare: Key Strategic Developments, 2015-2017
Table 49.Cepheid: Key Strategic Developments, 2015-2017
Table 50.Illumina Incorporated: Key Strategic Developments, 2015-2017
Table 51.Dako A/S: Key Strategic Developments, 2015-2017
Table 52.Biogen: Key Strategic Developments, 2015-2017
Table 53.Exagen Diagnostics Inc.: Key Strategic Developments, 2015-2017
Table 54.Decode Genetics Inc.: Key Strategic Developments, 2015-2017
Table 55.Genelex Corporation: Key Strategic Developments, 2015-2017
Table 56.Qiagen Incorporated: Key Strategic Developments, 2015-2017
Table 57.Celera Diagnostics: Key Strategic Developments, 2015-2017
Table 58.DNA Direct Inc : Key Strategic Developments, 2015-2017
Table 59.Affymetrix Incorporated: Key Strategic Developments, 2015-2017
Table 60.Agendia N.V.: Key Strategic Developments, 2015-2017


List of Figures

List of Figures
Figure 1.Personalized Medicine (PM) Market,By Product, 2012 & 2022 ($Million)
Figure 2.Personalized Medicine (PM) Market, By Region, 2016, ($Million)
Figure 3.ABBOTT LABORATORIES: Net Revenues, 2014-2016 ($Million)
Figure 4.ABBOTT LABORATORIES: Net Revenue Share, By Segment, 2016
Figure 5.ABBOTT LABORATORIES: Net Revenue Share, By Geography, 2016
Figure 6.GE Healthcare: Net Revenues, 2014-2016 ($Million)
Figure 7.GE Healthcare: Net Revenue Share, By Segment, 2016
Figure 8.GE Healthcare: Net Revenue Share, By Geography, 2016
Figure 9.Cepheid: Net Revenues, 2014-2016 ($Million)
Figure 10.Cepheid: Net Revenue Share, By Segment, 2016
Figure 11.Cepheid: Net Revenue Share, By Geography, 2016
Figure 12.Illumina Incorporated: Net Revenues, 2014-2016 ($Million)
Figure 13.Illumina Incorporated: Net Revenue Share, By Segment, 2016
Figure 14.Illumina Incorporated: Net Revenue Share, By Geography, 2016
Figure 15.Biogen: Net Revenues, 2014-2016 ($Million)
Figure 16.Biogen: Net Revenue Share, By Segment, 2016
Figure 17.Biogen: Net Revenue Share, By Geography, 2016

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*